Systemic lupus erythematosus (SLE) and diabetes intersect in three main ways: lupus itself roughly doubles the risk of type 2 diabetes through chronic inflammation, the glucocorticoid therapy used to control flares is a powerful cause of steroid-induced hyperglycemia, and the kidneys and cardiovascular system in both diseases compound each other. Hydroxychloroquine, an anchor lupus drug, modestly lowers diabetes risk. Pregnancy planning requires extra care when both diseases coexist.
How Lupus Raises Diabetes Risk
- Chronic systemic inflammation contributes to insulin resistance
- Prolonged glucocorticoid courses are the most concrete driver
- Reduced physical activity during flares contributes to weight gain
- Antiphospholipid syndrome amplifies cardiovascular risk
- Lupus nephritis can independently affect glucose handling
- Shared genetic susceptibility within autoimmune polyglandular clusters
Relative Risk in Numbers
| Population | Approximate Relative Risk vs General Population |
|---|---|
| SLE — overall type 2 diabetes risk | ~2-fold higher |
| SLE on long-term glucocorticoids | 2 to 4-fold higher |
| SLE on hydroxychloroquine | ~16 percent lower than other SLE patients |
| SLE with lupus nephritis | Higher cardiovascular and metabolic risk |
| SLE + antiphospholipid syndrome | Major cardiovascular risk |
Steroid-Induced Hyperglycemia in Lupus
- Prednisone, methylprednisolone, and dexamethasone all raise blood glucose
- Effect is dose-dependent and most pronounced after breakfast and lunch when daily prednisone is taken in the morning
- Pulse therapy for severe flares can cause acute, dramatic spikes — sometimes unmasking diabetes
- Hyperglycemia may persist for the duration of the steroid course and resolve afterward
- Short-term insulin is often the safest treatment during high-dose steroid courses
- Reassess oral diabetes medication needs after each steroid taper
Hydroxychloroquine and Glucose
- Hydroxychloroquine (Plaquenil) is recommended for nearly all patients with SLE
- Modest insulin-sensitizing effect; one large rheumatoid arthritis study (Wasko 2007) showed a roughly 16 percent reduction in new diabetes among users
- Does not replace standard diabetes therapy but provides a small protective bonus
- Long-term users need annual ophthalmologic screening for retinal toxicity
- Generally well tolerated in patients who also have diabetes
Other Lupus Drugs and Glucose
- Methotrexate — generally glucose-neutral; monitor liver and kidney function
- Mycophenolate mofetil — generally glucose-neutral
- Azathioprine — generally glucose-neutral; rare pancreatitis risk
- Belimumab (Benlysta) — no significant glucose effect
- Rituximab — no significant glucose effect
- Anifrolumab — no significant glucose effect
- Voclosporin (lupus nephritis) — can increase blood pressure; monitor closely
Lupus Nephritis and Diabetic Kidney Disease
- Lupus nephritis affects 30 to 60 percent of patients with SLE at some point
- When combined with diabetic kidney disease, decline accelerates
- Tight blood-pressure control (often under 130/80 mm Hg) helps
- ACE inhibitors or ARBs provide both renal protection and proteinuria reduction
- SGLT2 inhibitors (dapagliflozin, empagliflozin) are now used in non-diabetic and diabetic kidney disease; emerging data in lupus nephritis is promising
- Avoid metformin if eGFR is below 30; reduce dose between 30 and 45
Cardiovascular Risk When Lupus and Diabetes Combine
- SLE alone roughly doubles cardiovascular risk independent of traditional factors
- Adding diabetes compounds the risk further
- Antiphospholipid syndrome (present in 30 to 40 percent of SLE) increases stroke and clotting risk
- Aggressive lipid management with a statin is usually indicated
- Aspirin therapy decisions depend on antiphospholipid status
- Blood-pressure targets are stricter than in low-risk populations
Pregnancy Planning
- Lupus should be quiet for at least six months before conception
- A1C should ideally be under 7 percent before pregnancy
- Antiphospholipid antibody panel — anticardiolipin, beta-2 glycoprotein, lupus anticoagulant
- Anti-Ro/SSA antibodies — risk for neonatal lupus and congenital heart block
- Hydroxychloroquine is continued during pregnancy
- Mycophenolate is teratogenic — must be switched to alternatives before conception
- ACE inhibitors/ARBs are stopped before or during pregnancy
- Coordinated rheumatology, endocrinology, and maternal-fetal medicine care
Self-Care That Helps Both Diseases
- Sun protection — UV exposure can trigger lupus flares
- Smoking cessation — smoking accelerates both lupus flares and diabetic complications
- Mediterranean-style diet supports both autoimmune and metabolic health
- Regular low-impact exercise during quiet disease periods
- Vaccination — pneumococcal, annual flu, shingles, and COVID-19 are important in immunosuppressed patients
- Sleep — irregular sleep worsens both flares and glucose
Related Reading
See our overview of complications and related conditions for related comorbidities, and our guides on treatment and A1C levels. Other autoimmune overlaps include rheumatoid arthritis, celiac disease, and multiple sclerosis.
The Bottom Line
Lupus raises type 2 diabetes risk roughly two-fold, driven by chronic inflammation and the glucocorticoids that often anchor flare treatment. Hydroxychloroquine modestly lowers diabetes risk and is recommended for nearly all lupus patients. Steroid courses should be matched with proactive glucose monitoring and often short-term insulin. When lupus nephritis combines with diabetic kidney disease, blood-pressure control and ACE inhibitor or ARB therapy slow the decline. Pregnancy planning with combined lupus and diabetes is high-stakes but feasible with coordinated specialist care.
